Payment overview · 2025
General Payments
$1,117.26
56 reported records · 23 companies
Healthcare provider profile · identity verified
James A Hicks, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEST COLUMBIA, SC · NPI 1649288226
Verified facts
What the public records show
CMS Open Payments records show James A Hicks, MD received $1,117.26 in general payments during 2025 across 56 reported records.
Novo Nordisk Inc accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $199.26 | 17.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $106.02 | 9.5% | 7 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $96.26 | 8.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.00 | 7.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.67 | 6.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.07 | 5.7% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $51.39 | 4.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.39 | 4.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.05 | 4.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.62 | 3.6% | 2 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $40.39 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.07 | 3.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.41 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.09 | 3.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.68 | 2.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.51 | 2.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $22.54 | 2.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $22.24 | 2.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.55 | 1.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.10 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.78 | 1.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $13.56 | 1.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $6.61 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,117.26 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $153.63 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $96.26 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $66.67 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $50.39 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.05 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.63 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.59 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.59 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| ROSA Normalized: rosa |
Device | Zimmer Biomet Holdings, Inc. | $40.39 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.25 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $31.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $10.17 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $6.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 341 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 94 |
| Gabapentin | Gabapentin | 275 | 74 |
| Omeprazole | Omeprazole | 267 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 207 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 205 | 52 |
| Tramadol Hcl | Tramadol Hcl | 196 | 49 |
| Lorazepam | Lorazepam | 195 | 38 |
| Prednisone | Prednisone | 183 | 106 |
| Furosemide | Furosemide | 172 | 61 |
| Trazodone Hcl | Trazodone Hcl | 166 | 39 |
| Losartan Potassium | Losartan Potassium | 163 | 45 |
| Metformin Hcl | Metformin Hcl | 163 | 48 |
| Lisinopril | Lisinopril | 157 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 50 |
| Simvastatin | Simvastatin | 136 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 42 |
| Clonazepam | Clonazepam | 124 | 22 |
| Meloxicam | Meloxicam | 111 | 33 |
| Sertraline Hcl | Sertraline Hcl | 106 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 43 |
| Ozempic | Semaglutide | 90 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 24 |
| Methocarbamol | Methocarbamol | 83 | 32 |
| Azithromycin | Azithromycin | 82 | 67 |
| Metformin Hcl Er | Metformin Hcl | 76 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 22 |
| Glimepiride | Glimepiride | 75 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 16 |
| Amoxicillin | Amoxicillin | 72 | 66 |
| Diazepam | Diazepam | 72 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 15 |
| Allopurinol | Allopurinol | 68 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 11 |
| Valsartan | Valsartan | 67 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 12 |
| Potassium Chloride | Potassium Chloride | 66 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Eliquis | Apixaban | 60 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 14 |
| Celecoxib | Celecoxib | 58 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 16 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Carvedilol | Carvedilol | 56 | 14 |
| Famotidine | Famotidine | 56 | 25 |
| Mounjaro | Tirzepatide | 56 | 11 |
| Benazepril Hcl | Benazepril Hcl | 53 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 14 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 13 |
| Clonidine Hcl | Clonidine Hcl | 43 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 38 |
| Meclizine Hcl | Meclizine Hcl | 40 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 12 |
| Januvia | Sitagliptin Phosphate | 30 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Temazepam | Temazepam | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,117.26 · 56 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CLOTTRIEVER BOLD CATHETER, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, FARXIGA, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, Heplisav-B, INJECTAFER, INSPIRE, JARDIANCE, Korlym, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, ROSA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error